FLCCC Vaccine Injury Protocol: First Line Therapies The full first line protocol for vaccine injury is as follows. Keep in mind, however, that the treatment must be individualized to the symptoms of each patient. As explained by Marik, the patient's response will determine future treatment and adjunct therapies. These are not symptom specific but rather listed in order of importance:10
Time Restricted Eating or periodic daily fasts. Fasting has a profound effect on promoting immune system homeostasis, partly by stimulating the removal of damaged cells and mitochondria and clearing misfolded and foreign proteins. Intermittent fasting likely has an important role in promoting the breakdown and elimination of the spike protein. Fasting is contraindicated in patients under 18 (impairs growth) and during pregnancy and breastfeeding.
Patients with diabetes, as well as those with serious underlying medical conditions, should consult their primary care provider prior to fasting, as changes in their medications may be required and these patients require close monitoring.
Ivermectin — 0.2 to 0.3 mg/kg, daily for up to 4 to 6 weeks. Ivermectin has potent anti-inflammatory properties. It also binds to the spike protein, aiding in the elimination by the host. It is likely that ivermectin and intermittent fasting act synergistically to rid the body of the spike protein.
Ivermectin is best taken with or just following a meal for greater absorption. A trial of ivermectin should be considered as first line therapy. It appears that patients can be grouped into two categories: i) ivermectin responders and ii) ivermectin nonresponders.
This distinction is important, as the latter are more difficult to treat and require more aggressive therapy. Due to the possible drug interaction between quercetin and ivermectin, these drugs should not be taken simultaneously (i.e., should be staggered morning and night).
Low dose naltrexone (LDN) — Begin with 1 mg/day and increase to 4.5 mg/day, as required. May take 2 to 3 months to see full effect. LDN has been demonstrated to have anti-inflammatory, analgesic and neuromodulating properties.
